160 related articles for article (PubMed ID: 27084958)
21. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study).
Ikeda K; Takahashi T; Yamada H; Matsui K; Sawada T; Nakamura T; Matsubara H;
Eur J Prev Cardiol; 2013 Dec; 20(6):1069-79. PubMed ID: 22689416
[TBL] [Abstract][Full Text] [Related]
22. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.
Pokrovsky SN; Afanasieva OI; Safarova MS; Balakhonova TV; Matchin YG; Adamova IYU; Konovalov GA; Ezhov MV
Atheroscler Suppl; 2017 Nov; 30():166-173. PubMed ID: 29096833
[TBL] [Abstract][Full Text] [Related]
23. Thresholds for Arterial Wall Inflammation Quantified by
van der Valk FM; Verweij SL; Zwinderman KA; Strang AC; Kaiser Y; Marquering HA; Nederveen AJ; Stroes ES; Verberne HJ; Rudd JH
JACC Cardiovasc Imaging; 2016 Oct; 9(10):1198-1207. PubMed ID: 27639759
[TBL] [Abstract][Full Text] [Related]
24. Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels.
Horiuchi Y; Hirayama S; Soda S; Seino U; Kon M; Ueno T; Idei M; Hanyu O; Tsuda T; Ohmura H; Miida T
J Atheroscler Thromb; 2010 Jul; 17(7):722-9. PubMed ID: 20523010
[TBL] [Abstract][Full Text] [Related]
25. 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?
Bangalore S; Fayyad R; Kastelein JJ; Laskey R; Amarenco P; DeMicco DA; Waters DD
Am J Med; 2016 Apr; 129(4):384-91. PubMed ID: 26551986
[TBL] [Abstract][Full Text] [Related]
26. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
27. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
[TBL] [Abstract][Full Text] [Related]
28. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
Ezhov MV; Safarova MS; Afanasieva OI; Pogorelova OA; Tripoten MI; Adamova IY; Konovalov GA; Balakhonova TV; Pokrovsky SN
Atheroscler Suppl; 2015 May; 18():163-9. PubMed ID: 25936321
[TBL] [Abstract][Full Text] [Related]
29. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
Sever PS; Poulter NR; Chang CL; Thom SA; Hughes AD; Welsh P; Sattar N;
J Am Coll Cardiol; 2013 Aug; 62(8):717-29. PubMed ID: 23948514
[TBL] [Abstract][Full Text] [Related]
31. Assessment of subclinical atherosclerotic cardiovascular disease in patients with ankylosing spondylitis.
Hatipsoylu E; Şengül İ; Kaya T; Karatepe AG; Akçay S; Isayeva L; Bozkaya G; Tatar E
Anatol J Cardiol; 2019 Sep; 22(4):185-191. PubMed ID: 31584431
[TBL] [Abstract][Full Text] [Related]
32. Sustained Improvement of Arterial Stiffness and Blood Pressure after Long-Term Rosuvastatin Treatment in Patients with Inflammatory Joint Diseases: Results from the RORA-AS Study.
Ikdahl E; Rollefstad S; Hisdal J; Olsen IC; Pedersen TR; Kvien TK; Semb AG
PLoS One; 2016; 11(4):e0153440. PubMed ID: 27093159
[TBL] [Abstract][Full Text] [Related]
33. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.
Shishehbor MH; Aviles RJ; Brennan ML; Fu X; Goormastic M; Pearce GL; Gokce N; Keaney JF; Penn MS; Sprecher DL; Vita JA; Hazen SL
JAMA; 2003 Apr; 289(13):1675-80. PubMed ID: 12672736
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
Ansell BJ; Navab M; Hama S; Kamranpour N; Fonarow G; Hough G; Rahmani S; Mottahedeh R; Dave R; Reddy ST; Fogelman AM
Circulation; 2003 Dec; 108(22):2751-6. PubMed ID: 14638544
[TBL] [Abstract][Full Text] [Related]
35. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease.
Mathieu S; Joly H; Baron G; Tournadre A; Dubost JJ; Ristori JM; Lusson JR; Soubrier M
Rheumatology (Oxford); 2008 Aug; 47(8):1203-7. PubMed ID: 18524805
[TBL] [Abstract][Full Text] [Related]
36. Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk.
Laufs U; Karmann B; Pittrow D
Clin Res Cardiol; 2016 Sep; 105(9):783-90. PubMed ID: 27120330
[TBL] [Abstract][Full Text] [Related]
37. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
38. Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Chironi G; Simon A; Gariepy J; Balice M; Del-Pino M; Levenson J
Am J Hypertens; 2005 Nov; 18(11):1476-81. PubMed ID: 16280285
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation.
Divecha H; Sattar N; Rumley A; Cherry L; Lowe GD; Sturrock R
Clin Sci (Lond); 2005 Aug; 109(2):171-6. PubMed ID: 15801904
[TBL] [Abstract][Full Text] [Related]
40. On-treatment C-reactive protein and HDL cholesterol levels in patients at intermediate cardiovascular risk: impact on carotid intima-media thickness.
Pirro M; Vaudo G; Lupattelli G; Pasqualini L; Mannarino MR; Schillaci G; Alaeddin A; Paciullo F; Fallarino F; Bagaglia F; Mannarino E
Life Sci; 2013 Sep; 93(8):338-43. PubMed ID: 23871987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
